Advertisement
U.S. markets open in 3 hours 16 minutes
  • S&P Futures

    5,068.50
    -12.50 (-0.25%)
     
  • Dow Futures

    38,876.00
    -117.00 (-0.30%)
     
  • Nasdaq Futures

    17,877.75
    -37.50 (-0.21%)
     
  • Russell 2000 Futures

    2,047.00
    +3.60 (+0.18%)
     
  • Crude Oil

    78.44
    -0.10 (-0.13%)
     
  • Gold

    2,038.40
    -4.30 (-0.21%)
     
  • Silver

    22.54
    -0.10 (-0.42%)
     
  • EUR/USD

    1.0845
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    4.2740
    0.0000 (0.00%)
     
  • Vix

    14.02
    +0.18 (+1.30%)
     
  • GBP/USD

    1.2665
    +0.0006 (+0.04%)
     
  • USD/JPY

    150.0160
    -0.6170 (-0.41%)
     
  • Bitcoin USD

    62,929.78
    +3,683.57 (+6.22%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,640.09
    +15.11 (+0.20%)
     
  • Nikkei 225

    39,166.19
    -41.84 (-0.11%)
     

New Alzheimer's drug touted

A new research note makes a bullish case for Biogen Idec's BIIB037 experimental drug for Alzheimer's disease. RBC Capital Markets predicted it will make a big splash at an Alzheimer's and Parkinson's diseases conference in France next week. The biotech will likely show "best in class" data for the drug when it makes its presentation on March 20, the report said, adding that BIIB037 could be "one of the biggest potential drugs in all of the biopharma industry" if it ends up making it to market. Biogen shares fell 1.5% to 408.11 .

Advertisement